Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ORIC |
---|---|---|
09:32 ET | 5171 | 10.46 |
09:34 ET | 440 | 10.55 |
09:36 ET | 100 | 10.39 |
09:38 ET | 200 | 10.4239 |
09:39 ET | 480 | 10.5094 |
09:41 ET | 200 | 10.52 |
09:45 ET | 6030 | 10.485 |
09:56 ET | 1930 | 10.5 |
09:57 ET | 100 | 10.45 |
10:01 ET | 800 | 10.5 |
10:03 ET | 1700 | 10.585 |
10:06 ET | 200 | 10.56 |
10:08 ET | 1580 | 10.44 |
10:10 ET | 300 | 10.45 |
10:12 ET | 200 | 10.45 |
10:17 ET | 1294 | 10.465 |
10:19 ET | 700 | 10.42 |
10:21 ET | 100 | 10.44 |
10:24 ET | 100 | 10.45 |
10:26 ET | 2463 | 10.555 |
10:30 ET | 100 | 10.51 |
10:33 ET | 300 | 10.48 |
10:35 ET | 100 | 10.51 |
10:37 ET | 900 | 10.535 |
10:39 ET | 800 | 10.55 |
10:42 ET | 1031 | 10.545 |
10:44 ET | 1367 | 10.67 |
10:46 ET | 200 | 10.67 |
10:48 ET | 200 | 10.69 |
10:51 ET | 1565 | 10.655 |
10:53 ET | 204 | 10.68 |
10:57 ET | 300 | 10.655 |
11:02 ET | 1000 | 10.6601 |
11:04 ET | 238 | 10.61 |
11:06 ET | 100 | 10.63 |
11:08 ET | 100 | 10.66 |
11:09 ET | 2104 | 10.67 |
11:15 ET | 100 | 10.675 |
11:18 ET | 200 | 10.66 |
11:20 ET | 500 | 10.68 |
11:22 ET | 200 | 10.62 |
11:24 ET | 100 | 10.65 |
11:26 ET | 200 | 10.59 |
11:27 ET | 500 | 10.59 |
11:33 ET | 118 | 10.61 |
11:38 ET | 100 | 10.6 |
11:40 ET | 1817 | 10.6 |
11:42 ET | 100 | 10.6351 |
11:44 ET | 485 | 10.67 |
11:51 ET | 100 | 10.675 |
12:02 ET | 400 | 10.67 |
12:03 ET | 100 | 10.69 |
12:05 ET | 100 | 10.72 |
12:07 ET | 300 | 10.72 |
12:09 ET | 235 | 10.71 |
12:12 ET | 351 | 10.66 |
12:14 ET | 213 | 10.67 |
12:16 ET | 100 | 10.65 |
12:18 ET | 100 | 10.67 |
12:25 ET | 1759 | 10.68 |
12:32 ET | 100 | 10.68 |
12:39 ET | 200 | 10.72 |
12:41 ET | 200 | 10.74 |
12:45 ET | 300 | 10.739 |
12:48 ET | 1191 | 10.71 |
12:52 ET | 831 | 10.73 |
12:54 ET | 203 | 10.73 |
12:56 ET | 2500 | 10.68 |
12:57 ET | 468 | 10.685 |
01:01 ET | 100 | 10.655 |
01:03 ET | 100 | 10.655 |
01:06 ET | 100 | 10.65 |
01:10 ET | 900 | 10.63 |
01:12 ET | 300 | 10.63 |
01:14 ET | 700 | 10.63 |
01:15 ET | 200 | 10.63 |
01:17 ET | 300 | 10.63 |
01:19 ET | 100 | 10.65 |
01:21 ET | 200 | 10.6425 |
01:24 ET | 100 | 10.67 |
01:26 ET | 1500 | 10.735 |
01:28 ET | 100 | 10.735 |
01:30 ET | 800 | 10.72 |
01:32 ET | 300 | 10.76 |
01:33 ET | 100 | 10.76 |
01:35 ET | 500 | 10.76 |
01:37 ET | 800 | 10.7764 |
01:39 ET | 700 | 10.75 |
01:42 ET | 200 | 10.74 |
01:44 ET | 100 | 10.75 |
01:48 ET | 246 | 10.7767 |
01:50 ET | 100 | 10.79 |
01:51 ET | 660 | 10.79 |
01:53 ET | 239 | 10.82 |
02:00 ET | 500 | 10.81 |
02:09 ET | 1842 | 10.8061 |
02:11 ET | 368 | 10.82 |
02:13 ET | 280 | 10.87 |
02:18 ET | 100 | 10.88 |
02:20 ET | 1601 | 10.8 |
02:26 ET | 300 | 10.78 |
02:27 ET | 1240 | 10.75 |
02:31 ET | 500 | 10.67 |
02:36 ET | 100 | 10.69 |
02:38 ET | 200 | 10.66 |
02:40 ET | 100 | 10.665 |
02:44 ET | 300 | 10.68 |
02:45 ET | 254 | 10.71 |
02:47 ET | 600 | 10.72 |
02:51 ET | 200 | 10.74 |
02:54 ET | 800 | 10.73 |
02:56 ET | 100 | 10.725 |
03:02 ET | 687 | 10.75 |
03:03 ET | 500 | 10.73 |
03:09 ET | 100 | 10.74 |
03:12 ET | 600 | 10.71 |
03:14 ET | 100 | 10.69 |
03:16 ET | 400 | 10.72 |
03:21 ET | 2125 | 10.68 |
03:27 ET | 300 | 10.665 |
03:30 ET | 670 | 10.665 |
03:32 ET | 679 | 10.63 |
03:34 ET | 571 | 10.62 |
03:36 ET | 509 | 10.61 |
03:38 ET | 300 | 10.6 |
03:39 ET | 200 | 10.6 |
03:43 ET | 200 | 10.61 |
03:45 ET | 554 | 10.6 |
03:48 ET | 4840 | 10.63 |
03:50 ET | 300 | 10.64 |
03:52 ET | 1120 | 10.625 |
03:54 ET | 700 | 10.68 |
03:56 ET | 2355 | 10.66 |
03:57 ET | 2022 | 10.6799 |
03:59 ET | 49947 | 10.65 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Oric Pharmaceuticals Inc | 697.7M | -6.0x | --- |
Rapport Therapeutics Inc | 695.0M | -12.1x | --- |
ProKidney Corp | 692.3M | -3.1x | --- |
Savara Inc | 691.3M | -9.8x | --- |
Scholar Rock Holding Corp | 685.9M | -3.9x | --- |
MBX Biosciences Inc | 713.1M | -16.2x | --- |
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $697.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.11 |
EPS | $-1.76 |
Book Value | $4.08 |
P/E Ratio | -6.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.